2/23/2024  5:35:38 PM Chg. +0.860 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
96.420EUR +0.90% 185,491
Turnover: 17.88 mill.
95.500Bid Size: 102 96.780Ask Size: 60 18.22 bill.EUR 1.38% 43.83

Business description

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
 

Management board & Supervisory board

CEO
Jean-Christophe Tellier
Management board
Sandrine Dufour, Charl van Zyl, Dhaval Patel, Emmanuel Caeymaex, Iris Löw-Friedrich, Jean Luc Fleurial, Kirsten Lund-Jurgensen, Denelle Waynick Johnson
Supervisory board
Jonathan Peacock, Fiona du Monceau, Jean-Christophe Tellier, Jan Berger, Maëlys Castella, Kay Davies, Albrecht De Graeve, Susan Gasser, Pierre Gurdjian, Charles-Antoine Janssen, Cyril Janssen, Cédric van Rijckevorsel, Ulf Wiinberg
 

Company data

Name: UCB SA
Address: Allée de la Recherche 60,B-1070 Brussels
Phone: +32-2-559-9999
Fax: +32-2-559-9900
E-mail: contactucb@ucb.com
Internet: www.ucb.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 44.83%
IPO date: -

Investor relations

Name: Antje Witte
IR phone: +32-2-559-9414
IR Fax: -
IR e-mail: investor-relations@ucb.com

Company calendar

CW 9 | 2/28/2024 4th Quarter/Annual Report
 

Main Shareholders

Other institutional investors
 
36.00%
Financiere de Tubize
 
35.00%
Wellington
 
8.00%
Retail investors
 
6.00%
BlackRock
 
5.00%
FMR
 
4.00%
Unidentified
 
3.00%
Treasury shares
 
3.00%